Stepping Up for Stem Cells

Within months, scientists will be able to compete for about $100 million in federal grants for research involving human embryonic stem cells (ESCs). Following President George W. Bush's decision last month to provide limited federal funding for human ES cell research, based on existing stem cell lines only, officials at the National Institutes of Health are rushing to finalize grant procedures, which will include a public registry database of 60-70 government-certified lines and their suppliers.

Written byTed Agres
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

"The more than 60 stem-cell lines are diverse, they're robust, and they're viable for research," announced Tommy G. Thompson, secretary of Health and Human Services, parent department of the NIH. "And we have great confidence that these existing lines will provide for very effective and productive research." Thompson said funding mechanisms will be in place by early next year and predicts a "ballpark" of $100 million in grants will be available. "We expect those grants to be given out very quickly after the first of the calendar year," Thompson said. Current NIH grantees might receive supplemental funding even sooner, assuming the appropriate procedures are in place, NIH spokesman Marc Stern added.

Despite this, officials remain optimistic. "It's a wonderful day for basic research," extolled Lana Skirboll, associate director for science policy at NIH. "We believe the best and the brightest will be now coming to this arena of research. [We're] ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies